Manufacturer
PFIZER MANUFACTURING BELGIUM NV,
Contents
Methylprednisolone Na succinate
Indication
Adjunctive therapy for short-term management of acute episode or exacerbation post-traumatic OA, synovitis or OA, RA eg, juvenile RA, acute & subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute gouty & psoriatic arthritis, ankylosing spondylitis. Exacerbation or maintenance therapy of SLE, acute rheumatic carditis, systemic dermatomyositis, polyarteritis nodosa, Good pasture's syndrome. Dermatologic, ophth, GI, resp & oncological diseases; allergic, edematous & shock states; hematologic, endocrine & nervous system disorders. Organ transplantation. TB meningitis, trichinosis, prevention of chemotherapy-induced nausea & vomiting.
Instruction
Methylprednisolone sodium succinate may be administered by intravenous (IV) injection or infusion, or by intramuscular (IM) injection.
Drug interaction
Altered metabolism by induction (up-regulation) or inhibition of CYP3A4 enzyme. Decreased hepatic clearance by CYP3A4 inhibitor. Increased hepatic clearance by CYP3A4 inducers. Increased acetylation rate & clearance of INH. Diminished & enhanced effects of oral anticoagulants. Antagonism of neuromuscular blocking effects of pancuronium & vecuronium. Reduced effects of anticholinesterases. Increase blood glucose conc. Increased plasma conc by PIs eg, indinavir & ritonavir. Induced HIV-protease inhibitors metabolism. Exacerbated endocrine changes w/ aminoglutethimide. Convulsions w/ cyclosporine. Increased GI bleeding & ulceration w/ NSAIDs. Increased high-dose aspirin clearance. Increased risk of hypoglycemia w/ K-depleting agents eg, diuretics, amphotericin B, xanthines or β2-agonists.
Malaysia
